Your browser doesn't support javascript.
loading
Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis.
Dubinsky, Marla C; Charles, Lorna; Selmaj, Krzysztof W; Comi, Giancarlo; Krakovich, Anthony; Rosen, Melissa; van der Woude, C Janneke; Mahadevan, Uma.
Affiliation
  • Dubinsky MC; Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Charles L; Bristol Myers Squibb, Princeton, NJ, USA.
  • Selmaj KW; Center for Neurology, Lodz, Poland.
  • Comi G; Department of Neurology, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.
  • Krakovich A; Department of Neurorehabilitation Sciences, Vita-Salute San Raffaele University and Casa di Cura Igea, Milan, Italy.
  • Rosen M; Bristol Myers Squibb, Princeton, NJ, USA.
  • van der Woude CJ; Bristol Myers Squibb, Princeton, NJ, USA.
  • Mahadevan U; Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, Netherlands.
Inflamm Bowel Dis ; 2024 Jan 24.
Article in En | MEDLINE | ID: mdl-38267826
This study evaluated pregnancy outcomes in patients with ulcerative colitis, Crohn's disease, or multiple sclerosis and in healthy volunteers treated with ozanimod. There was no increased incidence of fetal abnormalities or adverse pregnancy outcomes with ozanimod exposure during early pregnancy.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Inflamm Bowel Dis Journal subject: GASTROENTEROLOGIA Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Inflamm Bowel Dis Journal subject: GASTROENTEROLOGIA Year: 2024 Document type: Article Affiliation country: Country of publication: